Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model

Human Gene Therapy

Volumn 9, Issue 8, 1998, Pages 1121-1130

  Turner, Joel G ^a,b   Tan, Jun ^a,b   Crucian, Brian E ^a,b   Sullivan, Daniel M ^a   Ballester, Oscar F ^a   Dalton, William S ^a   Yang, Ning Sun ^c   Burkholder, Joseph K ^d   Yu, Hua ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d Geniva   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOLISTIC TRANSFORMATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DNA TRANSFECTION; DNA TRANSFER; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MELANOMA B16; MOUSE; MYELOMA CELL; NONHUMAN; PRODUCTIVITY; SKIN FIBROBLAST; T LYMPHOCYTE;

ANIMALIA; MURINAE;

EID: 0032550792     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.8-1121     Document Type: Article

References (9)

1. ARUGA, A., ARUGA, E., and CHANG, A.E. (1997). Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant. Cancer Res. 57, 3230-3237.
2. BERGENBRANT, S., YI, Q., OSTERBORG, A., BJORKHOLM, M., OSBY, E., MELLSTEDT, H., and LEFVERT, A.K. (1996). Modulation of an anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br. J. Haematol. 92, 840-846.
3. BERNS, A.J., CLIFT, S., COHEN, L.K., DONEHOWER, R.C., DRAN-OFF, G., HAUDA, K.M., JAFFEE, E.M., LAZENBY, A.J., LEVITSKY, H.I., and MARSHALL, F.F. (1995). Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 6, 347-368.
4. BRICHARD, V., VAN PEL, A., WOLFEL, T., WOLFEL, C., DE PLAEN, E., LETHE, B., COULIE, P., and BOON, T. (1993). The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178, 489-495.
5. BRICHARD, V.G., WARNIER, G., VAN PEL, A., MORLIGHEM, G., LUCAS, S., and BOON, T. (1995). Individual difference in the orientation of the cytolytic T cell response against mouse tumor P815. Eur. J. Immunol. 25, 664-671.
6. CHANG, A.E., SONDAK, V.K., BISHOP, D.K., NICKOLOFF, B.J., MULLIGAN, R.C., and MULE, J.J. (1996). Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum. Gene Ther. 7, 773-792.
7. COULIE, P.G., BRICHARD, V., VAN PEL, A., WOLFEL, T., SCHNEIDER, J., TRAVERSARI, C., MATTEI, S., DE PLAEN, E., LURQUIN, C., and SZIKORA, J.P. (1994). A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35-42.
8. WOLFEL, T., HAUER, M., KLEHMANN, E., BRICHARD, V., ACKERMANN, B., KNUTH, A., BOON, T., and MEYER ZUM BUSCHENFELDE, K.H. (1993). Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int. J. Cancer 55, 237-244.
9. ZITVOGEL, L., TAHARA, H., ROBBINS, P.D., STORKUS, W.J., CLARKE, M.R., NALESNIK, M.A., and LOTZE, M.T. (1995). Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155, 1393-1403.